Drug intelligence / Profile preview

Fluval P + Fluval AB

Development stage: Unknown
Lead developer: Fluart Innovative Vaccines
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

Fluval P + Fluval AB is a combination of two influenza vaccines. Fluval P is a monovalent influenza vaccine containing 6-17 μg hemagglutinin (HA) per 0.5 ml with aluminum phosphate gel adjuvant, specifically targeting pandemic influenza strains (such as A/California/7/2009 NYMC X 179/A (H1N1)). Fluval AB is a trivalent seasonal influenza vaccine containing 6-15 μg HA per strain per 0.5 ml with aluminum phosphate gel adjuvant, targeting seasonal influenza strains (A/H1N1, A/H3N2, and B).

Brand names: Fluval P + Fluval AB

Targets

HA0 (Influenza B virus hemagglutinin)

Beyond the preview

Go deeper on Fluval P + Fluval AB.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fluval P + Fluval AB.

Explore the full profile